17b-hydroxysteroid dehydrogenase 3 deficiency

Raloxifene (Evista) is currently being studied in a large randomized study comparing it to tamoxifen for prevention of breast cancer in postmenopausal women. Information on this study is available at (604) 822-7997. It is not approved or proven for use in women with a history of breast cancer, nor is it approved for prevention. The osteoporosis study [ 30] suggested a 76% decrease in the rate of breast cancer in a group of women who were not at high risk. However, this study was in older women, had very small numbers, was not planned to have breast cancer as a primary endpoint, and needs confirmation. Both raloxifene and tamoxifen can cause hot flushes and dyspareunia, and are not appropriate to treat these menopausal symptoms. Both drugs are effective in improving heart and bone outcomes, and raloxifene is licensed for use in osteoporosis. We are all waiting for the perfect SERM that will prevent osteoporosis, cardiac disease, Alzheimer’s, and breast cancer, relieve hot flushes, vaginal complaints, and depression, and not increase the risk of thromboembolic events or uterine cancer. Unfortunately that SERM is not yet available.

Principal supervisor : Exotoxicology (UniSA) (4) ; Carcinogenesis (UniSA) (2) ; Cancer prevention (UniSA) (2) ; Pharmacy (UniSA) (1) ; Oncology (Flinders) (1) ; Pharmacology (UniSA) (3) ; Medicinal Chemistry (UniSA) (1) ;
Associate supervisor : Ecotoxicology (UniSA) (2) ; Cancer prevention (UniSA) (1) ; Autism (UniSA) (1) ; Biochemistry (UniSA) (1) ; Drug Discovery (UniSA) (2) ; Pharmacology (Flinders) (1) ; Genetics (UniSA) (1) ;

A total of 32 healthy male volunteers (age range 20-30 years) were enrolled in a 1-week open, randomized, placebo-controlled study comparing finasteride (Proscar), a 5 alpha-reductase inhibitor, with Permixon, the plant extract of Serenoa repens. The objective of the study was to evaluate the effect of single and multiple doses of the drugs on the inhibition of 5 alpha-reductase as assessed by serum dihydrotestosterone level determination. Following baseline measurements on day 1, the subjects were randomized to finasteride 5 mg once a day (n = 10), Permixon 80 mg x 2 twice a day (n = 11), or to placebo once a day (n = 11) for 7 days. Serum testosterone and dihydrotestosterone levels, were determined on day 1 (baseline and 12 h) and on days 2 (24 h), 3 (48 h), 4 (72 h), 6 (120 h), and 8 (168 h). After 12 h, a single dose of finasteride 5 mg reduced the serum dihydrotestosterone level by 65% (p = ). The decreases ranged from -52 to -60% with multiple doses of finasteride 5 mg once a day (p = ). As in the placebo group, there was no effect of Permixon on the serum dihydrotestosterone level. No significant difference was detected between finasteride and Permixon or between finasteride and placebo with respect to serum testosterone , except on days 3 and 6, respectively (p = ). However, the corresponding serum testosterone levels remained within the normal ranges.

17b-hydroxysteroid dehydrogenase 3 deficiency

17b-hydroxysteroid dehydrogenase 3 deficiency

Media:

17b-hydroxysteroid dehydrogenase 3 deficiency17b-hydroxysteroid dehydrogenase 3 deficiency17b-hydroxysteroid dehydrogenase 3 deficiency17b-hydroxysteroid dehydrogenase 3 deficiency17b-hydroxysteroid dehydrogenase 3 deficiency

http://buy-steroids.org